Abbisko Cayman Unveils Promising Cancer Drug Findings

Abbisko Cayman Limited (HK:2256) has released an update.

Abbisko Cayman Limited’s subsidiary, Abbisko Therapeutics, presented promising Phase I study results of their oral PD-L1 inhibitor, ABSK043, at the ESMO Asia 2024. The study highlighted ABSK043’s favorable safety and strong anti-tumor activity, particularly in non-small cell lung cancer patients with high PD-L1 expression. This development positions Abbisko as a potential leader in the oral PD-L1 inhibitor market, with further investigations underway.

For further insights into HK:2256 stock, check out TipRanks’ Stock Analysis page.